Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Clinical trial NCT05017103 · TERMINATED

Trial details

NCT number: NCT05017103
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Undifferentiated Pleomorphic Sarcoma Metastatic Undifferentiated Pleomorphic Sarcoma Recurrent Undifferentiated Pleomorphic Sarcoma Unresectable Undifferentiated Pleomorphic Sarcoma

Start date: 2021-07-13
Primary completion: 2024-02-20
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.